tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), Cytokinetics (CYTK) and Neoleukin Therapeutics (NLTX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Boston Scientific (BSXResearch Report), Cytokinetics (CYTKResearch Report) and Neoleukin Therapeutics (NLTXResearch Report).

Boston Scientific (BSX)

In a report released today, Michael Matson from Needham maintained a Hold rating on Boston Scientific. The company’s shares closed last Tuesday at $43.84.

According to TipRanks.com, Matson is a 4-star analyst with an average return of 6.6% and a 49.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $49.20, which is a 13.4% upside from current levels. In a report issued on February 2, Leerink Partners also maintained a Hold rating on the stock with a $45.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Cytokinetics (CYTK)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Cytokinetics, with a price target of $48.00. The company’s shares closed last Tuesday at $38.23.

According to TipRanks.com, Butler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.5% and a 40.0% success rate. Butler covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Aquestive Therapeutics, and Quoin Pharmaceuticals.

Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $58.27, representing a 46.4% upside. In a report issued on February 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $69.00 price target.

Neoleukin Therapeutics (NLTX)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Neoleukin Therapeutics, with a price target of $21.00. The company’s shares closed last Tuesday at $2.96, close to its 52-week low of $2.80.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 7.8% and a 34.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as CASI Pharmaceuticals, Autolus Therapeutics, and Nektar Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neoleukin Therapeutics with a $21.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BSX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed